title: Effectiveness of oral propafenone for the prevention of atrial fibrillation after coronary artery bypass grafting.
abstract: The efficacy and safety of oral propafenone for the prevention of atrial fibrillation (AF) were tested in a group of 293 patients who underwent coronary artery bypass grafting. Patients were randomized to placebo or 1 of 2 doses of propafenone. Patients treated with propafenone 675 mg/day compared with placebo had a nonsignificantly reduced incidence of AF and did not have a reduction in length of stay. Adverse events and discontinuations for untoward events were equal among the 3 groups.
authors.affiliation: Main Line Health Heart Center and the Lankenau Hospital and Institute for Medical Research, Wynnewood, Pennsylvania 19096, USA. koweypr@mlhheart.org
authors.forename: Peter R
authors.initials: PR
authors.lastname: Kowey
authors.forename: Daniel
authors.initials: D
authors.lastname: Yannicelli
authors.forename: Ezra
authors.initials: E
authors.lastname: Amsterdam
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage*; D001281:Atrial Fibrillation / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D001026:Coronary Artery Bypass / Q000009:adverse effects*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D015994:Incidence; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D011405:Propafenone / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D000889:Anti-Arrhythmia Agents; D011405:Propafenone